Augmentation of Anterior Cruciate Ligament Reconstruction Using Mesenchymal Stem Cells and Collagen Matrix Carrier (BioACL)
ACL Tear
About this trial
This is an interventional treatment trial for ACL Tear
Eligibility Criteria
Inclusion Criteria:
- Patients between the ages of 14 and 50 who are scheduled to have ACL reconstruction by one of the investigating physicians
Exclusion Criteria:
- Patients requiring ACL and posterior cruciate ligament combined surgery
- Patients with a history of an autoimmune disease, diabetes, a blood/clotting disorder
- History of previous surgery on the injured knee
- Patients outside of the acceptable age range of this study
Sites / Locations
- Andrews Research and Education FoundationRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Other
ACL reconstruction utilizing stump-derived mesenchymal stem cells
Standard of care ACL reconstructive surgery
This is the test group of this study. These participants will receive the augmented ACL reconstruction treatment involving extraction and injection of mesenchymal stem cells. Stem cell tissue will be harvested from each participant using the GraftNet device intraoperatively. During the intra-articular preparation phase of the reconstruction, the stem cell tissue will be applied to the ACL graft using a bovine collagen matrix.
This is the control group of this study. These participants will receive standard ACL reconstructive surgery without any augmentations.